Roivant Sciences (ROIV) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ROIV Roivant Sciences

Watchlist

12.110
-0.010-0.08%

Close Dec 4 16:00 ET

11.763
-0.347-2.86%

Post 20:01 ET

8.82BMarket Cap2.08P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Seeking AlphaDec 3 11:49 ET
Roivant Sciences Ends Namilumab Study Due to Inefficacy
TipRanksDec 3 07:47 ET
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
WSJDec 3 07:35 ET
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
ReutersDec 3 07:05 ET
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
ReutersDec 3 07:00 ET
Express News | Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis
ReutersDec 3 07:00 ET

Comments

Jaguar8

Dec 3 06:07

NEWS

$Roivant Sciences (ROIV.US)$
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Movers and Shakers

Apr 2 07:16

Columns Today's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More

Morning Movers
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Moomoo AI

Jan 5 04:55

The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.

Have Roivant Sciences Insiders Been Selling Stock?

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ROIV Roivant Sciences

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target